Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

127 sites for NCT02568267

ALK Fusion, +4 more biomarkers

Malignant Solid Tumor

entrectinib

targeted therapy

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

267 sites for NCT03994796

AKT1 Amplification, +52 more biomarkers

Malignant Solid Tumor

abemaciclib, +2 more drugs

targeted therapy

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

132 sites for NCT03093116

ALK Fusion, +4 more biomarkers

Malignant Solid Tumor

repotrectinib

targeted therapy

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

95 sites for NCT03213652

ALK Fusion, +2 more biomarkers

Histiocytic and Dendritic Cell Neoplasm, +2 more conditions

ensartinib

targeted therapy

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

8 sites for NCT05118789

ROS1 Fusion

Malignant Solid Tumor, +1 more condition

NUV-520

targeted therapy

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

15 sites for NCT04919811

ROS1 Fusion

Malignant Solid Tumor

taletrectinib

targeted therapy

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

48 sites for NCT04632992

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types